TACE With Dicycloplatin(TP21) in Unresectable HCC

NCT05472896 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

332

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: cTACE
DRUG: Dicycloplatin (TP21)
DRUG: Epirubicin

Sponsor

Gao-jun Teng